ERBB2 and breast cancer: reported a large cohort of patients with HER2+ early-stage BC (n=1156), enrolled in the NSABP B-31 phase III clinical trial, that received doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab (20).